First in class anti-fungal agents

F2G has identified a novel fungal target essential for DNA synthesis, and so fungal growth and survival. The company has identified novel inhibitors of this enzyme with the lead candidate F901318 in Phase II clinical trials. F901318 has the potential to be the first new class of anti-fungal agent for over 30 years.

CEO  Francesco Maria Lavino

Advent Contact  Kaasim Mahmood

Private Companies
19 December 2022 in F2G, Press Release, Private Companies

F2G Announces FDA Filing Acceptance of New Drug Application for Olorofim for the Treatment of Invasive Fungal Infections

Press Release.   Application submitted under priority review with PDUFA target action date set for June 17, 2023 NDA submission is based on positive data from ongoing Phase 2b open-label…
Read More
4 August 2022 in F2G, Press Release, Private Companies

F2G Announces $70 Million Financing to Advance Development and Commercialization of New Antifungal Agent Olorofim

Press Release.   MANCHESTER, UK, 4 August 2022 – F2G Ltd, a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat life-threatening rare fungal infections…
Read More
16 May 2022 in F2G, Press Release, Private Companies

Shionogi & Co., Ltd. and F2G Ltd., Enter Strategic Collaboration to Develop and Commercialize the New Antifungal Agent Olorofim in Europe and Asia

Press Release.   Shionogi to conduct clinical trials, subsequent registration and commercialization of olorofim for invasive aspergillosis IA in Europe and Asia F2G to receive u pfront payment of $100…
Read More
12 April 2021 in F2G, Press Release, Private Companies

Francesco Maria Lavino appointed Chief Executive Officer of F2G Ltd

Press Release.   Brings substantial pharmaceutical expertise to lead the development and commercialization of olorofim in the USA Ian Nicholson stepping down to pursue non-executive roles MANCHESTER, UK / VIENNA,…
Read More